Emerg Infect Dis. Oseltamivir-Resistant Influenza Virus A (H1N1), Europe, 2007?08 Season.

[sharon sanders]

Re: Emerg Infect Dis. Oseltamivir-Resistant Influenza Virus A (H1N1), Europe, 2007?08 Season.

I am going to insist that users refrain from posting any insulting/derogatory comments.

Everyone knows the rules here.

 

[sharon sanders]

Re: Emerg Infect Dis. Oseltamivir-Resistant Influenza Virus A (H1N1), Europe, 2007?08 Season.

The fact is that H1N1 developed oseltamivir resistance in a fairly quick amount of time throughout the world. This does not bode well for societies that are relying on this drug as a major component for the treatment of pandemic influenza.

It also shows how quickly viruses can dramatically change.

The reality is that we need to be priming our populations now with the best match we can formulate for an eventual pandemic strain.

We also need to "get back to basics" when thinking about all disaster preparedness such as: hand washing, stockpiles of essential supplies, healthy life styles, social distancing, and the development of a close network of friends and family.

We can argue about the "why", but we can not ignore the "what".

 

[Giuseppe]

Re: Emerg Infect Dis. Oseltamivir-Resistant Influenza Virus A (H1N1), Europe, 2007?08 Season.

The fact is that H1N1 developed oseltamivir resistance in a fairly quick amount of time throughout the world. This does not bode well for societies that are relying on this drug as a major component for the treatment of pandemic influenza.

It also shows how quickly viruses can dramatically change.

The reality is that we need to be priming our populations now with the best match we can formulate for an eventual pandemic strain.

We also need to "get back to basics" when thinking about all disaster preparedness such as: hand washing, stockpiles of essential supplies, healthy life styles, social distancing, and the development of a close network of friends and family.

We can argue about the "why", but we can not ignore the "what".

That is also the conclusion of the paper:

Although oseltamivir remains a valuable influenza antiviral agent, the emergence of natural resistance shifts attention from oseltamivir to other antiviral agents and to improved vaccination (e.g., greater vaccination coverage, more immunogenic and broadly reacting vaccines) in the fight against seasonal and pandemic influenza.